Eli Lilly's weight-loss drug could generate billions in sales
Investor's Business Daily — March 2, 2024, 12:01 AM UTC
Summary: Eli Lilly's new weight-loss drug could generate over $62 billion in 2030 sales, with a potential increase to $81 billion when factoring in next-generation drugs. Analyst Geoff Meacham raised the stock's price target to 1,000, citing a competitive advantage over rivals. Eli Lilly and Novo Nordisk lead the obesity treatment space, with a projected 7% of U.S. adults using GLP-1 agonist drugs for weight loss by 2030. The stock has a 29% year-to-date increase and a Relative Strength Rating of 95.
Article metrics
The article metrics are deprecated.
I'm replacing the original 8-factor scoring system with a new and improved one. It doesn't use the original factors and gives much better significance scores.